ReviewHaematologica2012
Molecular pathogenesis of Waldenstrom's macroglobulinemia.
Review in Haematologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 40 citations in OpenAlex.
- Rare presentation of double-clonal Waldenström macroglobulinemia with pulmonary embolism: A case report.Open life sciences · 2023Article
- Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation.Haematologica · 2022Article
- Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.Diagnostics (Basel, Switzerland) · 2022Review
- Preneoplastic somatic mutations includingScience advances · 2022Article
- Primary Isolated Lymphoplasmacytic Lymphoma (LPL) of the Stomach: A Case Report.The American journal of case reports · 2020Article
- Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.PloS one · 2018Article
- Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.Leukemia · 2017Article
- Waldenström macroglobulinemia: biology, genetics, and therapy.Blood and lymphatic cancer : targets and therapy · 2016Review
- [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.Cancer biology & therapy · 2015Article
- MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Leukemia · 2014Review
- MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.Leukemia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Waldenström's macroglobulinemia is an indolent, lymphoproliferative disease, characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and high immunoglobulin M production. While technological advances over the past several decades have dramatically improved the possibilities of studying the molecular basis of Waldenström's macroglobulinemia, the pathogenesis of the disease remains fragmented. Undoubtedly, research has been successful in uncovering underlying aberrations and deregulated mechanisms in this disease, providing useful information for identifying biomarkers for disease diagnosis, risk stratification and therapeutic intervention, but there is still a long way to go before the pathogenesis of Waldenström's macroglobulinemia is fully revealed. In addition, the low number of in vitro or in vivo models significantly challenges extensive analysis. In this manuscript, we review the molecular basis of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.